Univariable and multivariable regression for progression or recurrence of cancer-associated SpVT within 1 year of SpVT diagnosis
| Characteristic . | Progression or recurrence, n (%) . | Unadjusted RR (95% CI) . | Adjusted∗ RR (95% CI) . |
|---|---|---|---|
| Age at thrombosis | |||
| ≤65 y | 50 (16.2) | Ref | Ref |
| >65 y | 44 (16.1) | 0.99 (0.69-1.44) | 0.78 (0.45-1.37) |
| Sex | |||
| Female | 32 (15.2) | Ref | Ref |
| Male | 62 (16.9) | 1.11 (0.75-1.64) | 1.13 (0.74-1.73) |
| Cirrhosis | |||
| Absent | 46 (14.2) | Ref | Ref |
| Present | 48 (18.7) | 1.32 (0.91-1.90) | 1.48 (0.83-2.64) |
| Abdominal surgery within past 3 mo | |||
| Absent | 92 (16.9) | Ref | Ref |
| Present | 2 (5.7) | 0.34 (0.09-1.32) | 0.43 (0.11-1.65) |
| Previous VTE | |||
| Absent | 88 (16.0) | Ref | Ref |
| Present | 6 (20.0) | 1.25 (0.60-2.63) | 1.34 (0.64-2.78) |
| Baseline creatinine | |||
| ≤1.0 | 82 (18.2) | Ref | Ref |
| >1.0 | 12 (9.2) | 0.51 (0.29-0.90) | 0.51 (0.25-1.04) |
| Recent systemic chemotherapy | |||
| Absent | 75 (16.1) | Ref | Ref |
| Present | 19 (16.4) | 1.02 (0.64-1.61) | 1.11 (0.68-1.81) |
| Use of antiplatelets at baseline | |||
| Absent | 77 (16.5) | Ref | Ref |
| Present | 17 (15.0) | 0.91 (0.56-1.48) | 0.93 (0.56-1.52) |
| Type of thrombus | |||
| Bland/mixed | 68 (15.5) | Ref | Ref |
| Tumor | 24 (20.9) | 1.35 (0.89-2.05) | 1.16 (0.76-1.79) |
| Thrombus occlusion | |||
| Partial | 16 (13.0) | Ref | Ref |
| Complete | 42 (15.9) | 1.22 (0.72-2.09) | 1.37 (0.79-2.37) |
| Anticoagulation within 2 wk | |||
| Absent | 69 (19.6) | Ref | Ref |
| Present | 25 (11.0) | 0.56 (0.37-0.86) | 0.55 (0.35-0.86) |
| Thrombocytopenia at baseline | |||
| None | 40 (12.9) | Ref | Ref |
| Platelets 75 × 103/μL - 99 × 103/μL | 8 (12.3) | 0.95 (0.47-1.94) | 0.89 (0.44-1.83) |
| Platelets 50 × 103/μL - 74 × 103/μL | 15 (20.8) | 1.61 (0.95-2.76) | 1.67 (0.97-2.88) |
| Platelets <50 × 103/μL | 6 (9.2) | 0.72 (0.32-1.62) | 0.76 (0.33-1.73) |
| Thrombocytopenia | |||
| None | 40 (12.9) | Ref | Ref |
| Platelets <100 × 103/μL | 29 (14.4) | 1.11 (0.71-1.73) | 1.14 (0.73-1.78) |
| Vessel involvement | |||
| Single | 77 (16.9) | Ref | Ref |
| Multiple | 17 (13.5) | 0.80 (0.49-1.30) | 0.79 (0.47-1.32) |
| Type of cancer | |||
| Hepatobiliary | 55 (17.1) | Ref | Ref |
| Pancreatic | 24 (19.1) | 1.11 (0.72-1.71) | 1.36 (0.85-2.19) |
| Luminal GI | 5 (10.2) | 0.60 (0.25-1.41) | 0.67 (0.27-1.66) |
| Other | 10 (11.8) | 0.69 (0.37-1.29) | 0.84 (0.44-1.61) |
| Characteristic . | Progression or recurrence, n (%) . | Unadjusted RR (95% CI) . | Adjusted∗ RR (95% CI) . |
|---|---|---|---|
| Age at thrombosis | |||
| ≤65 y | 50 (16.2) | Ref | Ref |
| >65 y | 44 (16.1) | 0.99 (0.69-1.44) | 0.78 (0.45-1.37) |
| Sex | |||
| Female | 32 (15.2) | Ref | Ref |
| Male | 62 (16.9) | 1.11 (0.75-1.64) | 1.13 (0.74-1.73) |
| Cirrhosis | |||
| Absent | 46 (14.2) | Ref | Ref |
| Present | 48 (18.7) | 1.32 (0.91-1.90) | 1.48 (0.83-2.64) |
| Abdominal surgery within past 3 mo | |||
| Absent | 92 (16.9) | Ref | Ref |
| Present | 2 (5.7) | 0.34 (0.09-1.32) | 0.43 (0.11-1.65) |
| Previous VTE | |||
| Absent | 88 (16.0) | Ref | Ref |
| Present | 6 (20.0) | 1.25 (0.60-2.63) | 1.34 (0.64-2.78) |
| Baseline creatinine | |||
| ≤1.0 | 82 (18.2) | Ref | Ref |
| >1.0 | 12 (9.2) | 0.51 (0.29-0.90) | 0.51 (0.25-1.04) |
| Recent systemic chemotherapy | |||
| Absent | 75 (16.1) | Ref | Ref |
| Present | 19 (16.4) | 1.02 (0.64-1.61) | 1.11 (0.68-1.81) |
| Use of antiplatelets at baseline | |||
| Absent | 77 (16.5) | Ref | Ref |
| Present | 17 (15.0) | 0.91 (0.56-1.48) | 0.93 (0.56-1.52) |
| Type of thrombus | |||
| Bland/mixed | 68 (15.5) | Ref | Ref |
| Tumor | 24 (20.9) | 1.35 (0.89-2.05) | 1.16 (0.76-1.79) |
| Thrombus occlusion | |||
| Partial | 16 (13.0) | Ref | Ref |
| Complete | 42 (15.9) | 1.22 (0.72-2.09) | 1.37 (0.79-2.37) |
| Anticoagulation within 2 wk | |||
| Absent | 69 (19.6) | Ref | Ref |
| Present | 25 (11.0) | 0.56 (0.37-0.86) | 0.55 (0.35-0.86) |
| Thrombocytopenia at baseline | |||
| None | 40 (12.9) | Ref | Ref |
| Platelets 75 × 103/μL - 99 × 103/μL | 8 (12.3) | 0.95 (0.47-1.94) | 0.89 (0.44-1.83) |
| Platelets 50 × 103/μL - 74 × 103/μL | 15 (20.8) | 1.61 (0.95-2.76) | 1.67 (0.97-2.88) |
| Platelets <50 × 103/μL | 6 (9.2) | 0.72 (0.32-1.62) | 0.76 (0.33-1.73) |
| Thrombocytopenia | |||
| None | 40 (12.9) | Ref | Ref |
| Platelets <100 × 103/μL | 29 (14.4) | 1.11 (0.71-1.73) | 1.14 (0.73-1.78) |
| Vessel involvement | |||
| Single | 77 (16.9) | Ref | Ref |
| Multiple | 17 (13.5) | 0.80 (0.49-1.30) | 0.79 (0.47-1.32) |
| Type of cancer | |||
| Hepatobiliary | 55 (17.1) | Ref | Ref |
| Pancreatic | 24 (19.1) | 1.11 (0.72-1.71) | 1.36 (0.85-2.19) |
| Luminal GI | 5 (10.2) | 0.60 (0.25-1.41) | 0.67 (0.27-1.66) |
| Other | 10 (11.8) | 0.69 (0.37-1.29) | 0.84 (0.44-1.61) |
Adjusted for age at thrombosis (continuous), sex, previous VTE, baseline creatinine (continuous), use of antiplatelets, use of therapeutic anticoagulants within 2 weeks of diagnosis, and type of cancer.